Opthea Files Notice of Annual General Meeting
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company developing therapies for retinal diseases, has filed its Notice of Annual General Meeting. Dr. Megan Baldwin, Executive Director, will retire from the Board at the conclusion of the annual general meeting on November 15, 2024, and has chosen not to seek re-election. Dr. Baldwin will continue her role as Founder and Chief Innovation Officer, focusing on advancing Opthea's innovation agenda.
The company is approaching anticipated sozinibercept wet AMD Phase 3 data readouts in 2025. Dr. Baldwin expressed pride in sozinibercept's potential as a breakthrough for wet AMD patients. Chairman Jeremy Levin acknowledged Dr. Baldwin's valuable contributions to the Board. Opthea is currently seeking a new director to fill the upcoming Board vacancy.
Opthea (ASX/NASDAQ: OPT), un'azienda biofarmaceutica in fase clinica che sviluppa terapie per le malattie retiniche, ha presentato il suo Avviso di Assemblea Generale Annuale. Dr. Megan Baldwin, Direttore Esecutivo, si ritirerà dal Consiglio alla conclusione dell'assemblea generale annuale il 15 novembre 2024, e ha deciso di non candidarsi per il rinnovo. Il Dr. Baldwin continuerà il suo ruolo di Fondatrice e Chief Innovation Officer, concentrandosi sull'avanzamento dell'agenda d'innovazione di Opthea.
L'azienda si sta avvicinando agli attesi risultati dei dati di fase 3 di sozinibercept per l'AMD umido nel 2025. Il Dr. Baldwin ha espresso orgoglio per il potenziale di sozinibercept come una svolta per i pazienti affetti da AMD umido. Il presidente Jeremy Levin ha riconosciuto il prezioso contributo del Dr. Baldwin al Consiglio. Opthea sta attualmente cercando un nuovo direttore per coprire il prossimo posto vacante nel Consiglio.
Opthea (ASX/NASDAQ: OPT), una empresa biofarmacéutica en fase clínica que desarrolla terapias para enfermedades retinianas, ha presentado su Aviso de Asamblea General Anual. Dr. Megan Baldwin, Directora Ejecutiva, se retirará de la Junta al finalizar la asamblea general anual el 15 de noviembre de 2024, y ha decidido no postularse para la reelección. La Dra. Baldwin continuará su papel como Fundadora y Directora de Innovación, centrándose en avanzar la agenda de innovación de Opthea.
La empresa se está acercando a las esperadas lecturas de datos de fase 3 de sozinibercept para AMD húmedo en 2025. La Dra. Baldwin expresó su orgullo por el potencial de sozinibercept como un avance para los pacientes con AMD húmedo. El presidente Jeremy Levin reconoció las valiosas contribuciones de la Dra. Baldwin a la Junta. Opthea está actualmente buscando un nuevo director para ocupar el próximo puesto vacante en la Junta.
Opthea (ASX/NASDAQ: OPT)는 망막 질환 치료제를 개발하는 임상 단계의 생명공학 회사로, 연례 총회 공고를 제출했습니다. 미건 볼드윈 박사는 2024년 11월 15일 연례 총회 종료시 이사진에서 퇴임하며 재선에 나서지 않기로 결정했습니다. 볼드윈 박사는 창립자이자 최고 혁신 책임자로서의 역할을 계속 수행하며, Opthea의 혁신 agenda를 발전시키는 데 집중할 것입니다.
회사는 2025년 소지니버셉트 습식 AMD 3상 데이터 발표를 앞두고 있습니다. 볼드윈 박사는 습식 AMD 환자에게 소지니버셉트가 혁신적인 대안이 될 수 있다는 점에 자부심을 표했습니다. 제레미 레빈 의장은 볼드윈 박사의 이사회에 대한 귀중한 기여를 인정했습니다. Opthea는 현재 다가오는 이사회 공석을 채울 새로운 이사를 찾고 있습니다.
Opthea (ASX/NASDAQ: OPT), une entreprise bio-pharmaceutique en phase clinique développant des thérapies pour les maladies rétiniennes, a déposé son Avis de Réunion Générale Annuelle. Dr. Megan Baldwin, Directrice Exécutive, prendra sa retraite du Conseil à la fin de l'assemblée générale annuelle le 15 novembre 2024 et a choisi de ne pas se représenter. Dr. Baldwin continuera son rôle de Fondatrice et Directrice de l'Innovation, en se concentrant sur l'avancement de l'agenda d'innovation d'Opthea.
L'entreprise se prépare à l'attente des résultats de l'étude de phase 3 de sozinibercept pour l’AMD humide en 2025. Dr. Baldwin a exprimé sa fierté quant au potentiel de sozinibercept en tant que percée pour les patients atteints d’AMD humide. Le Président Jeremy Levin a reconnu les précieuses contributions de Dr. Baldwin au Conseil. Opthea recherche actuellement un nouveau directeur pour combler le prochain poste vacant au Conseil.
Opthea (ASX/NASDAQ: OPT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das Therapien für Netzhauterkrankungen entwickelt, hat seine Einladung zur Jahresversammlung eingereicht. Dr. Megan Baldwin, Geschäftsführerin, wird nach Abschluss der Jahresversammlung am 15. November 2024 aus dem Vorstand ausscheiden und hat sich entschieden, nicht zur Wiederwahl anzutreten. Dr. Baldwin wird ihre Rolle als Gründerin und Chief Innovation Officer fortsetzen und sich auf die Förderung von Opheas Innovationsagenda konzentrieren.
Das Unternehmen steht kurz vor den erwarteten Phase-3-Datenlesungen von sozinibercept für nasse AMD im Jahr 2025. Dr. Baldwin drückte ihren Stolz auf das Potenzial von sozinibercept als Durchbruch für Patienten mit nasser AMD aus. Vorsitzender Jeremy Levin würdigte die wertvollen Beiträge von Dr. Baldwin zum Vorstand. Opthea sucht derzeit einen neuen Direktor, um die bevorstehende Vakanz im Vorstand zu besetzen.
- Approaching Phase 3 data readouts for sozinibercept in wet AMD treatment in 2025
- Dr. Megan Baldwin continuing as Founder and Chief Innovation Officer to lead innovation strategy
- None.
Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election
As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea’s innovation agenda
MELBOURNE, Australia and PRINCETON, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the filing of the Notice of the Annual General Meeting and Explanatory Notes distributed to shareholders for the Company’s annual general meeting to be held virtually on Friday, 15 November 2024.
Opthea’s current Executive Director, Dr. Megan Baldwin, PhD, MAICD, will retire from the Board at the conclusion of the annual general meeting in accordance with the ASX Listing Rules. Dr. Baldwin has decided not to seek re-election to the Board. As Founder and Chief Innovation Officer, Dr. Baldwin remains an integral and important part of the Company’s senior executive team as the Company approaches the anticipated sozinibercept wet AMD Phase 3 data readouts in 2025.
“I look forward to focusing my efforts on leading Opthea’s innovation agenda in search of the next bold therapeutic approach in ophthalmology,” said Dr. Baldwin, Founder and Chief Innovation Officer, Opthea. “I am proud that sozinibercept could represent a breakthrough for millions of wet AMD patients to see better, a dream that I have nurtured over so many years.”
“I want to express my sincere appreciation for the contributions Dr. Baldwin has made as a member of the Board of Directors,” concluded Jeremy Levin, D.Phil, MB BChir, Chairman of the Opthea Board of Directors. “Her leadership and insights have been very valuable helping to guide the Company through pivotal moments over the years. As the Company approaches an inflection point with the sozinibercept Phase 3 data readout, Dr. Baldwin will continue to advance Opthea’s broader innovation strategy.”
Opthea is in the process of identifying a new director to fill the vacancy on the Board following Dr. Baldwin’s retirement from the Board.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Inherent risks of Investment in Biotechnology Companies
There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.
Forward Looking Statements
This announcement contains certain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The words “expect”, “believe”, “should”, “could”, “may”, “will”, “plan” and other similar expressions are intended to identify forward-looking statements. Forward-looking statements in this announcement include statements regarding the anticipated sozinibercept topline data timing for the two Phase 3 pivotal trials in wet AMD and Opthea’s innovation agenda. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. They involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Opthea and its directors and management and may involve significant elements of subjective judgment and assumptions as to future events that may or may not be correct. These statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to future capital requirements, the development, testing, production, marketing and sale of drug treatments, regulatory risk and potential loss of regulatory approvals, ongoing clinical studies to demonstrate sozinibercept’s potential safety, tolerability and therapeutic efficacy, clinical research organization and labor costs, intellectual property protections, and other factors that are of a general nature which may affect the future operating and financial performance of the Company including risk factors set forth in Opthea’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 30, 2024, as amended on September 20, 2024, and other future filings with the SEC. Actual results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Subject to any continuing obligations under applicable law or any relevant ASX listing rules, Opthea disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this announcement to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based, except as otherwise required by applicable law.
Authorized for release to ASX by Frederic Guerard, Pharm D, CEO
Investor and Media Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: pjkelleher@lifesciadvisors.com
Phone: 617-430-7579
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
When is Opthea's (OPT) Annual General Meeting scheduled for 2024?
What major change is happening to Opthea's (OPT) Board of Directors?
What is the status of Opthea's (OPT) sozinibercept for wet AMD treatment?
What role will Dr. Megan Baldwin continue to play at Opthea (OPT) after retiring from the Board?
